Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, March 26, 2020
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
Wednesday, March 25, 2020
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
Monday, March 23, 2020
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
Thursday, March 19, 2020
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan
Tuesday, February 25, 2020
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
Friday, February 21, 2020
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
Wednesday, January 29, 2020
Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc. Using Liquid Biopsy to Accelerate Next-Generation Drug Discovery and Development
Thursday, January 23, 2020
Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation
Monday, January 20, 2020
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: